This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Osthus, R. C. Articles by Dang, C. V. Search for Related Content PubMed PubMed Citation Articles by Osthus, R. C. Articles by Dang, C. V.

The Myc Target Gene JPO1/CDCA7 Is Frequently Overexpressed in Human Tumors and Has Limited Transforming Activity In vivo

¹ Program in Human Genetics and Molecular Biology, ² Division of Hematology, ³ Departments of Medicine, Cell Biology, ⁴ Pathology, and ⁵ Comparative Medicine, ⁶ The Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: Chi V. Dang, Ross Research Building, Room 1032, 720 Rutland Avenue, Baltimore, MD 21205. Phone: 410-955-2773; Fax: 410-955-0185; E-mail: cvdang{at}jhmi.edu.

MYC is frequently overexpressed in human cancers, but the downstream events contributing to tumorigenesis remain incompletely understood. MYC encodes an oncogenic transcription factor, of which target genes presumably contribute to cellular transformation. Although Myc regulates about 15% of genes and combinations of target genes are likely required for tumorigenesis, we studied in depth the expression of the Myc target gene, JPO1/CDCA7, in human cancers and its ability to provoke tumorigenesis in transgenic mice. JPO1/CDCA7 is frequently overexpressed in human cancers, and in particular, its expression is highly elevated in chronic myelogenous leukemia blast crisis as compared with the chronic phase. In murine lymphoid tissues, ectopic human JPO1/CDCA7 expression resulted in a 2-fold increased risk of lymphoid malignancies at 1 year. The transgene, which was driven by the H2-K promoter, exhibited leaky expression in nonlymphoid tissues such as kidney. We observed a significant increased incidence of transgenic animal solid tumors, which were not seen in littermate controls. These observations suggest that JPO1/CDCA7 may contribute to Myc-mediated tumorigenesis.

This article has been cited by other articles:

				C. D. Johnson, A. Esquela-Kerscher, G. Stefani, M. Byrom, K. Kelnar, D. Ovcharenko, M. Wilson, X. Wang, J. Shelton, J. Shingara, et al. The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells Cancer Res., August 15, 2007; 67(16): 7713 - 7722. [Abstract] [Full Text] [PDF]

				G. N. Maertens, P. Cherepanov, and A. Engelman Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin J. Cell Sci., June 15, 2006; 119(12): 2563 - 2571. [Abstract] [Full Text] [PDF]